Labiotech.eu

News and Trends 15 Jun 2022

Biotech companies to benefit from Third Rock Ventures $1.1B fund

U.S. company Third Rock Ventures has closed Third Rock Ventures Fund VI, raising $1.1 billion. Fund VI will continue Third Rock’s core strategy to discover, launch and build new companies focused on improving the lives of patients. “An important differentiator for Third Rock is the strength and maturity of our ideation ecosystem,” said Reid Huber, […]

June 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Jun 2022

NZ biotech company develops Johne’s Disease assay

New Zealand biotech company Pictor Limited has been developing an accurate, affordable multiplexed diagnostic test for Johne’s Disease. Also known as Mycobacterium avium subspecies paratuberculosis (MAP) – Johne’s disease costs the New Zealand dairy industry upwards of NZ$80 million (US$50 million) a year in lost production. A global issue, Johne’s disease is a contagious, chronic, […]

June 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Jun 2022

Biotech Acquisition Company and Blade Therapeutics merger collapses

A proposed merger between Biotech Acquisition Company (BAC) and Blade Therapeutics, Inc. has been terminated with immediate effect. BAC said it intends to continue to pursue a business combination with another appropriate target. Michael Shleifer, chairman and CEO of BAC, and co-founder and managing partner of SPRIM Global Investments said, “We wish Blade continued success […]

June 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Jun 2022

New EY report outlines challenges for biotech

Although the biotech industry performed strongly during the COVID-19 pandemic, it now faces challenges to valuations and access to capital. This is according to the 32nd edition of the Beyond Borders report produced by Ernst & Young LLP (EY US). The report, which EY said is a ‘moment-in-time’ snapshot of the industry, says despite the […]

June 13, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 13 Jun 2022

GSK positive on RSV vaccine for older adults

GSK plc has announced positive headline results from its AReSVi 006 phase III trial. AReSVi 006 is a phase III trial investigating GSK’s respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above. GSK said no unexpected safety concerns were observed. Dr Hal Barron, chief scientific officer and president, R&D, GSK, said, […]

June 13, 2022 - 3 minutesmins - By Jim Cornall

In Depth 13 Jun 2022

DNA synthesis: tackling the main bottleneck in biology research

A wave of new technologies to synthesize DNA faster, more cheaply and more accurately could have a far-reaching impact across all areas of biology research. More than ten years ago, Sylvain Gariel was working for the French oil company TotalEnergies, engineering microorganisms to produce biofuels. It was tedious work. “You had to introduce hundreds of […]

June 13, 2022 - 10 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Jun 2022

Expansion into Europe for BlueRock Therapeutics

BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has established a new site for cell therapy innovation on Bayer’s campus in Berlin, Germany. The move comes as part of the company’s growth strategy. A multidisciplinary BlueRock team will be set up during 2022 to provide clinical development and operational […]

June 10, 2022 - 2 minutesmins - By Jim Cornall

Inside Labiotech 10 Jun 2022

Beyond Biotech – the new Labiotech podcast

Labiotech.eu has just gone global with its coverage, and now we are gearing up for the first Labiotech.eu podcast. According to Spotify, in 2021 there were 1.2 million podcasts launched. So does the world need another one? We’d like to think the answer is yes! We are trying to ensure our new podcast, Beyond Biotech, […]

June 10, 2022

News and Trends 9 Jun 2022

Ziphius Vaccines and University of Antwerp to work on RNA-based delivery methods

Belgian biopharma firm Ziphius Vaccines is set to collaborate with the University of Antwerp to research and develop a lipid library for optimized delivery systems of self-amplifying RNA-based drugs (saRNA) and therapeutics. Messenger RNA (mRNA) vaccines deliver genetic instructions to cells to create proteins that then train the immune system against a pathogen, such as […]

June 9, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 9 Jun 2022

Amaroq Therapeutics ‘hits early milestones’ in cancer treatment

New Zealand biotech company Amaroq Therapeutics said it is progressing towards clinical trials following a promising initial development phase. The company, a start-up spun out of the University of Otago, is focused on developing a new class of therapeutics that target long non-coding RNAs (lncRNA) in cancer. Sarah Diermeier, chief scientific officer and founder of […]

June 9, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 9 Jun 2022

New Forbion life sciences fund hits €470M

European life sciences venture capital firm Forbion, has announced the first €470M ($500M) close of its Forbion Growth Opportunities Fund II. The fund will focus on investing in late-stage European life sciences companies. The new fund has attracted several new institutional investors, including pension funds PME and PMT, the Ewing Marion Kauffman Foundation and Reggeborgh, […]

June 9, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 9 Jun 2022

Cocuus raises funds to upscale alt-protein 3D bioprinting technology

Spanish start-up Cocuus has raised €2.5M ($2.7M) in its pre-Series A funding round. The funds will be used to scale up its 3D bioprinting process for producing plant or cell-based animal protein food analogs. The company recently completed the Eatable Adventures acceleration program, one of the top three global accelerators for foodtech start-ups. Eatable Adventures […]

June 9, 2022 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Biotech companies to benefit from Third Rock Ventures $1.1B fund

NZ biotech company develops Johne’s Disease assay

Biotech Acquisition Company and Blade Therapeutics merger collapses

New EY report outlines challenges for biotech

GSK positive on RSV vaccine for older adults

DNA synthesis: tackling the main bottleneck in biology research

Expansion into Europe for BlueRock Therapeutics

Beyond Biotech – the new Labiotech podcast

Ziphius Vaccines and University of Antwerp to work on RNA-based delivery methods

Amaroq Therapeutics ‘hits early milestones’ in cancer treatment

New Forbion life sciences fund hits €470M

Cocuus raises funds to upscale alt-protein 3D bioprinting technology

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!